Trial Profile
An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2021
Price :
$35
*
At a glance
- Drugs Ataluren (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Sponsors PTC Therapeutics
- 18 Dec 2021 This trial has been completed in Italy global end of the trial 2017-06-05 as per European Clinical Trials Database record.
- 30 May 2017 Planned End Date changed from 1 Jun 2019 to 1 May 2017.
- 30 May 2017 Planned primary completion date changed from 1 Jun 2019 to 1 May 2017.